Shamburg News · 8-K filed Nov 12, 2026, 4:26 PM EST
Candel Therapeutics Enters $50 Million At-the-Market Sales Agreement With Jefferies
CADL · Candel Therapeutics, Inc.
- Financing
- Material agreement
- Materiality: medium
On November 12, 2026, Candel Therapeutics, Inc. entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to sell common stock with an aggregate offering price of up to $50,000,000 through Jefferies as sales agent. The agreement amends and restates the 2025 Sales Agreement, under which the company had sold approximately $50,000,000 of shares as of November 12, 2026. Jefferies will receive a fixed commission of 3.0% of gross proceeds, and sales will be made under a prospectus supplement to an effective Form S-3 registration statement.
Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0001193125-26-458522.
Written from the filing by Shamburg Markets. Figures are as reported by the company.